NewAmsterdam Pharma Company N.V.NAMSNASDAQ
Loading
Year-over-year research & development expense growth
Latest
24.61%
↑ 202% vs avg
Percentile
P74
Within normal range
Streak
2 qtr
Consecutive growthAccelerating
Average
8.15%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 24.61% |
| Q3 2025 | 12.56% |
| Q2 2025 | -38.51% |
| Q1 2025 | 28.24% |
| Q4 2024 | -2.26% |
| Q3 2024 | -6.98% |
| Q2 2024 | -9.55% |
| Q1 2024 | 2.76% |
| Q4 2023 | -4.79% |
| Q3 2023 | 26.30% |
| Q2 2023 | -15.04% |
| Q1 2023 | 42.45% |
| Q4 2022 | 0.00% |
| Q3 2022 | 77.09% |
| Q2 2022 | -5.30% |
| Q1 2022 | 71.32% |
| Q4 2021 | 3.49% |
| Q3 2021 | 88.16% |
| Q2 2021 | 1.16% |
| Q1 2021 | 0.00% |
| Q4 2020 | -100.00% |
| Q3 2020 | 0.00% |
| Q2 2020 | 0.00% |
| Q1 2020 | 0.00% |